TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03797651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard DAPT
Description: Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very-short DAPT less than 1 month after PCI
Description: Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
Study: NCT02929953

Intervention type: OTHER
Intervention: chart review
Description: data from charts and from registries will be compared

Intervention type: OTHER
Intervention: chart review
Description: data from charts and from registries will be compared
Study: NCT04527952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online handouts describing how to follow each diet for 1 week each
Description: Participants will receive handouts via email about how to follow each diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online handouts describing how to follow each diet for 1 week each
Description: Participants will receive handouts via email about how to follow each diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online handouts describing how to follow each diet for 1 week each
Description: Participants will receive handouts via email about how to follow each diet
Study: NCT04435925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
Study: NCT02192515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 10 mg
Description: One tablet of APD356 10 mg will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 10 mg
Description: One tablet of APD356 10 mg will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg
Description: One tablet of APD356 XR-20 mg will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 10 mg matching Placebo
Description: One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg matching Placebo
Description: One tablet of APD356 XR matching placebo will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 20 mg
Description: Two tablets of APD356 10 mg will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 20 mg matching Placebo
Description: Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg (orange tablet)
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20mg (orange tablet, fed state)
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
Study: NCT03485924

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA with ROSE
Description: EUS-FNA with ROSE vs EUS-FNB without ROSE

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB without ROSE
Description: EUS-FNA with ROSE vs EUS-FNB without ROSE
Study: NCT00333125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)
Description: One drop in the study eye(s) once daily, 9 PM, for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
Description: One drop in the study eye(s) twice daily for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: One drop in the study eye(s) once daily for 6 weeks
Study: NCT01451606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To serve as placebo for duloxetine. Administration schedule same as for active drug.
Study: NCT02424396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01243164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program
Description: The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
Study: NCT03986970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis
Study: NCT04484961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR)
Description: The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
Study: NCT01063049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatorade/Miralax
Description: Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatorade/Miralax
Description: Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuLytely
Description: Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
Study: NCT01384981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pulmonary rehabilitation
Study: NCT03019406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa (GZ419829)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV
Study: NCT04055064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose control nutritional shake, nutrition education
Description: Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
Study: NCT01598766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16 Channel SPEEDER Flex Coil
Description: This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
Study: NCT00774046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Induction: 30mg/m2 after the end of HiDAC day 1 and day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
Study: NCT00812994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: SSRI antidepressant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00537394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90mg subcutaneously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90mg subcutaneously twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Enfuvirtide
Description: 90mg subcutaneously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir
Description: Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir
Description: Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Two 100-mg tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Two 100-mg tablets twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine
Description: Two 100-mg tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Dosage dependent on regimen in which maraviroc is included

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Dosage dependent on regimen in which maraviroc is included

Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: Dosage dependent on regimen in which maraviroc is included
Study: NCT04517123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Prone Positioning
Study: NCT04357743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chin supported Arm ergometry with pursed lip breathing
Description: The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm ergometry with pursed lip breathing
Description: The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week.
Study: NCT01623102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and gemcitabine combination with Bevacizumab
Description: Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine combined with cisplatin chemotherapy
Description: Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
Study: NCT03611738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
Study: NCT01468285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets b.i.d., six weeks treatment
Study: NCT03631602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antifungal prophylaxis
Description: posaconazole oral suspension vs itraconazole oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antifungal prophylaxis
Description: posaconazole oral suspension vs itraconazole oral solution
Study: NCT00784563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Description: The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval training
Description: Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
Study: NCT03404817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Study: NCT02228681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg daily by mouth on alternating weeks (even numbered) weeks
Study: NCT01780181

Intervention type: DRUG
Intervention: Chemotherapy
Description: treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W

Intervention type: DRUG
Intervention: Chemotherapy
Description: treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
Study: NCT02458703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis.
Study: NCT03819998

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of Fetuin-A level in serum
Description: Fetuin A level will be measured in blood of the PCOS women

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of Fetuin-A level in serum
Description: Fetuin A level will be measured in blood of the PCOS women
Study: NCT02228681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg once a day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate
Description: 200 mg daily by mouth
Study: NCT02060721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10mg, oral tablet, once daily
Study: NCT03638453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PediCARE
Description: PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care per hospital guidelines.
Study: NCT04412863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection